Caracterización del deseo sexual en mujeres climatéricas de un centro de salud rural / Characterization of sexual desire in climacteric women in a rural health center

OBJETIVO GENERAL: Caracterizar el deseo sexual en mujeres climatéricas de un centro de salud rural. METODOLOGÍA: Estudio no exploratorio descriptivo - transversal, que comprende mujeres entre 45 a 64 años que se controlan en un CESFAM Rural, 2016. La muestra fue de 146 mujeres que contestaron una encuesta auto aplicada, entre ellos el test del deseo sexual inhibido de M&J. Los datos fueron analizados con el software estadístico SPSS versión 22.0. RESULTADOS: Se encuestó a un total de 146 mujeres climatéricas, con un promedio de edad de 51.8 años, de ellas un 64.4% había tenido su menopausia. De las encuestadas sólo un 19,9% presentó inhibición del deseo sexual. La inhibición del deseo sexual se presentó con mayor frecuencia en mujeres que llevaban en promedio 29,3 años con sus parejas, aquellas que presentaban morbilidad crónica, y aquellas que reconocieron tener síntomas somáticos, psicológicos y urogenitales asociados a la menopausia. CONCLUSIÓN: En la evaluación del deseo sexual se debe considerar que existen varios factores que en él influyen y también una gran gama de instrumentos que pretenden medirlo. La mayoría de las usuarias climatéricas rurales (65,1%) no presentan inhibición del deseo sexual. Existen factores que pueden fomentar y causar una inhibición del deseo sexual, mientras otros pueden ayudar a evitar su aparición. Es fundamental conocer y manejar estos factores, con la finalidad de ayudar a la mujer climatérica a tener una mejor calidad de vida.

OBJECTIVE: To characterize the sexual desire in climacteric women of a rural health center. METHODOLOGY: Descriptive - transversal non - exploratory study, comprising women between 45 and 64 years old who are controlled at a Rural CESFAM, 2016. The sample was 146 women who answered a self - administered survey, including the M & J inhibited sex drive test. The data were analyzed with the statistical software SPSS version 22.0. RESULTS: A total of 146 climacteric women were surveyed, with a mean age of 51.8 years, of which 64.4% had had their menopause. Of the respondents, only 19.9% showed inhibition of sexual desire. Inhibition of sexual desire occurred more frequently in women who had on average 29.3 years with their partners, those with chronic morbidity, and those who recognized having somatic, psychological and urogenital symptoms associated with menopause. CONCLUSION: In the evaluation of sexual desire, it should be considered that there are several factors that influence it and also a wide range of instruments that aim to measure it. Most rural climateric users (65.1%) do not present inhibition of sexual desire. There are factors that can encourage and cause inhibition of sexual desire, while others can help prevent it from appearing. It is essential to know and manage these factors, in order to help climacteric women to have a better quality of life.

The phase angle of the electrical impedance is a predictor of long-term survival in dialysis patients.

INTRODUCTION: Protein-energy malnutrition is a risk factor for mortality in dialysis patients; however, its clinical assessment has not been well defined. Electrical bioimpedance (EBI) is a non-invasive and objective procedure, which is increasingly being used for this assessment. OBJECTIVE: The aim of this study is to analyse the relationship between the phase angle determined by EBI at a frequency of 50kHz (AF50) and other nutritional parameters, and prospectively evaluate its ability as a marker for long-term mortality. PATIENTS AND METHODS: We included 164 patients (127 on haemodialysis and 37 on peritoneal dialysis) who underwent an EBI analysis while simultaneously determining inflammation and nutrition parameters. The Charlson comorbidity index was then calculated. RESULTS: In the linear correlation analysis, we found that the AF50 had a direct association with lean mass, intracellular water, extracellular water and interdialytic weight gain, while having an inverse association with age and fat mass. Patients with AF50 >8º had a better nutritional status, were younger and had significantly longer survival at the six-year follow-up. Among the patients studied, both the AF50 and the other body composition parameters were better in peritoneal dialysis than in haemodialysis, but these differences may be attributable to the fact that the first patients were younger. In the multivariate analysis, only the AF50 <8º and comorbidity adjusted for age persisted as independent risk factors for mortality. CONCLUSIONS: We conclude that AF50 has a good correlation with nutritional parameters and is a good marker of survival in dialysis patients. Nevertheless, intervention studies are needed to demonstrate if the improvement in EBI parameters is associated with better survival.

El ángulo de fase de la impedancia eléctrica es un predictor de supervivencia a largo plazo en pacientes en diálisis / The phase angle of the electrical impedance is a predictor of long-term survival in dialysis patients

Introducción: La malnutrición calórico-proteica es un factor de riesgo de mortalidad en pacientes en diálisis, sin embargo, su valoración clínica no ha sido bien definida. La bioimpedancia eléctrica (BIE) es un procedimiento no invasivo y objetivo, cada vez más empleado en su valoración. Objetivo: El objetivo de este estudio es analizar la relación entre el ángulo de fase determinado por BIE a una frecuencia de 50 kHz (AF50) con otros parámetros de nutrición y valorar prospectivamente su capacidad como marcador pronóstico de mortalidad a largo plazo. Pacientes y métodos: Incluimos a 164 pacientes, 127 en hemodiálisis y 37 en diálisis peritoneal, a los que se les realiza un análisis de BIE al tiempo que se solicitan parámetros de inflamación y nutrición y se calcula el índice de comorbilidad de Charlson. Resultados: En el análisis de correlación lineal, encontramos que el AF50 tiene una asociación directa con la masa magra, con el agua intracelular, con el agua extracelular y con la ganancia de peso interdiálisis, mientras que se asocia de forma inversa con la edad, con la masa grasa y con el log PCR. Los pacientes con AF50 >8o presentan un mejor estado nutricional, son más jóvenes y tienen una supervivencia significativamente mejor a los seis años de seguimiento. Entre los pacientes (..) (AU)

Introduction: Protein-energy malnutrition is a risk factor for mortality in dialysis patients; however, its clinical assessment has not been well defined. Electrical bioimpedance (EBI) is a non-invasive and objective procedure, which is increasingly being used for this assessment. Objective: The aim of this study is to analyse the relationship between the phase angle determined by EBI at a frequency of 50kHz (AF50) and other nutritional parameters, and prospectively evaluate its ability as a marker for long-term mortality. Patients and methods: We included 164 patients (127 on haemodialysis and 37 on peritoneal dialysis) who underwent an EBI analysis while simultaneously determining inflammation and nutrition parameters. The Charlson comorbidity index was then calculated. Results: In the linear correlation analysis, we found that the AF50 had a direct association with lean mass, intracellular water, extracellular water and interdialytic weight gain, while having an inverse association with age and fat mass. Patients with AF50 >8o had a better nutritional status, were younger and had significantly longer survival at the six-year follow-up. Among the patients studied, both the AF50 and the other body composition parameters were better in peritoneal dialysis than in haemodialysis, but these differences may be attributable to the fact that the first patients were younger. In the multivariate analysis, only the AF50 <8o and comorbidity adjusted for age persisted as independent risk factors for mortality. Conclusions: We conclude that AF50 has a good correlation with nutritional parameters and is a good marker of survival in dialysis patients. Nevertheless, intervention studies are needed to demonstrate if the improvement in EBI parameters is associated with better survival (..) (AU)

Factors predicting mortality in elderly patients on dialysis.

UNLABELLED: Elderly patients are increasingly enrolled in dialysis programs and present a series of special characteristics due to their high morbidity and mortality. OBJECTIVE: To describe the characteristics of incident dialysis patients aged >75 years, their comorbidities and their admissions, with a view to determining the factors that influence their course and mortality. PATIENTS AND METHODS: The study included all patients aged >75 years who started dialysis in our center since January 2000. The mean duration of follow-up was 3.3 +/- 2.2 years. Data were collected on incident comorbidity, admissions and their causes. A total of 139 patients were included, with a mean age of 78.6 +/- 2.6 years (67.6% males, 33.8% diabetic and 7.9% on peritoneal dialysis). Three groups were established according to age: 75-79, 80-85 and >85 years. The most frequent comorbidities were chronic obstructive pulmonary disease (25.9%), ischemic heart disease (25.2%), heart failure (25.9%), neoplasms (23.7%), peripheral vascular disease (23.7%), cerebrovascular disease (18.7%) and arterial hypertension (81%). The Charlson index was calculated, not adjusted for age, and comorbidity tertiles were established. RESULTS: During follow-up, the patients presented 0.82 +/- 0.99 admissions/patient/year, with a duration of 12.1 +/- 20.6 days/patient/year. The main causes of admission were infection (33%), vascular access problems (27%) and peripheral vascular events (14%). A total of 61 patients died (44%), and 4 underwent kidney transplantation (2.9%). The mean duration of follow-up of the transplanted patients was 3.6 +/- 1.8 years. The main causes of death were infection (32%), cardiovascular problems (28.3%) and neoplastic disease (11.3%). The global survival rate was 90, 82 and 53% after 1, 2 and 5 years, respectively. No significant differences in survival or annual admission rate were found in relation to age group and dialysis technique. In contrast, the annual admission rate and days of admission were directly correlated to the Charlson index (p = 0.009 and p = 0.032, respectively). No significant differences in the Charlson index were found between the patients on hemodialysis and those subjected to peritoneal dialysis. In the univariate model, the factors associated to mortality were diabetes, chronic obstructive pulmonary disease, heart failure and the Charlson index. In the multivariate model, only the Charlson index remained as an independent predictive factor (p = 0.006). CONCLUSIONS: Unlike the general population, age does not influence mortality or admissions in elderly patients on dialysis. Incident comorbidity is the factor exerting the greatest influence upon mortality and admissions. Advanced age in itself should not be regarded as an excluding factor for starting dialysis.

El frasco humidificador como sistema de humidificación del gas inspirado no cumple con las recomendaciones. Evaluación y comparación de tres sistemas de humidificación. Estudio de laboratorio / The humidifier bottle as humidification system of the inspired gas does not meet with the recommendations. Evaluation and comparison of three humidification systems. Laboratory study

Objetivos. Demostrar que el frasco humidificador (FH), como sistema de humidificación del gas inspirado, no alcanza los valores mínimos de humedad relativa (HR), humedad absoluta (HA) y temperatura (Tº) recomendados por la literatura. Secundariamente, comparar el rendimiento del FH y dos sistemas activos de humidificación (SAH). Materiales y métodos. Las variables principales fueron T° del agua, HR, Tº y HA del gas entregado. Se realizaron mediciones a diferentes niveles de Tº, volumen de agua y flujos. Resultados. El FH no alcanzó los valores recomendados de HR 100%, HA 30 mg/l y Tº 31ºC. El SAH sin circuito calefaccionado alcanzó valores recomendados en el NIVEL III con flujos de 20-60lpm, y en el NIVEL II con flujos de 20-30lpm. El SAH con circuito calefaccionado logró valores sugeridos en los NIVELES II y III (20-60lpm). Se encontró diferencia significativa (p<0,001 Global) para flujo, Tº y tipo de humidificador. El modelo ANOVA arrojó significación estadística (p<0,001) del término interacción de flujo y tipo de humidificador en cada nivel de Tº. Conclusiones. El FH no acondiciona el gas de acuerdo a lo recomendado. El mejor rendimiento fue con 300 ml y flujo de 1 lpm: Tº 23,92(±0,69), HR 74,02%(±6,53) y HA 16,02 mg/l (±1,86), estos valores apenas superan el 50% de lo mínimo sugerido en la literatura. Los SAH acondicionaron el gas adecuadamente. El modelo ANOVA arroja que existen otros factores involucrados en mantener la HA y que la significación varía en cada tipo de humidificador a cada nivel de flujo(AU)

Objetive. To demonstrate that humidifier bottle (HB) as inspired gas humidification system does not attain the minimum values of relative humidity (RH), absolute humidity (AH) and temperature (Tº) as recommended by the literature. Furthermore, to compare the HB performance with two active humidification systems (AHS). Materials and Methods. Main variables were: water Tº, RH, Tº and AH of delivered gas. Measurements were made at different levels of Tº, water and flows volume. Results. Recommended values of RH 100%, AH 30 mg/l and Tº 31º C were not reached by the HB. AHS without heating circuit reached recommended values in LEVEL III with flows of 20-60 lpm, and in LEVEL II with flows of 20-30lpm. AHS with heating circuit obtained recommended values in LEVELS II and III (20-60lpm). A significant difference (p<0.001 Global) for flow, Tº and humidifier type was found. ANOVA model showed statistical evidence (p<0.001) of interaction between flow and type of humidifier in each Tº level. Conclusions. The HB does not condition gas in accordance with recommended values. The best performance was with 300ml and 1lpm flow: Tº 23.92 (±0.69), RH 74.02% (±6.53) and AH 16.02 mg/l (±1.86) and these values hardly exceed the 50% of minimum recommended by literature. AHS conditioned gas in a proper way. ANOVA model shows that there exist other factors involved to maintain AH and that there are important differences between each type of humidifier and each flow level.(AU)

Hemodiafiltración en línea secuencial (HDF-OL-S): una nueva opción terapéutica / No disponible

La hemodiafiltración en línea proporciona una alta eficacia depurativa de moléculas de mediano y gran peso molecular. Existe consenso sobre la necesidad de conseguir al menos 20 L de ultrafiltración en postdilución y tasas de reducción de B2-microglobulina mayores del 70%. Desafortunadamente muchos pacientes tienen un acceso vascular inadecuado siendo muy difícil lograr esos volúmenes de ultrafiltración sin complicaciones clínicas. El objetivo de este trabajo fue conseguir un volumen de ultrafiltración equivalente a 20 L en postdilucional, mediante la técnica «Secuencial» (HDF-OL-S) que comienza siendo postdilucional y cuando la PTM alcanza los 250 mmHg se trasforma en predilucional. Se realizó una sesión de hemodiálisis de alto flujo (HD-HF), una de hemodiafiltración postdilucional (HDF-OL-P) y otra sesión en modo secuencial a 16 pacientes durante 3 semanas consecutivas, en la sesión de mitad de semana. Se compararon los rendimientos de eliminación de pequeñas y medianas moléculas entre las diferentes técnicas. Se midió la presión prefiltro (PPF) mediante manómetro predializador. No encontramos diferencias en el Kt/V, tasa de reducción de urea y de creatinina entre las3 técnicas. La tasa de reducción de B2-microglobulina y mioglobina fue significativamente mayor tanto en HDFOL-P como en HDF-OL-S con respecto a la HD-HF, no habiendo diferencias entre ambas técnicas de HDF. Existió una correlación directa entre PTM y PPF a lo largo de la sesión en todas las técnicas. La PPF horaria se correlacionaba mejor que PTM con los niveles basales de albúmina sérica, hematocrito y porcentaje de hemoconcentración al final de la diálisis. La HDF-OL-S es una técnica de hemodiálisis con los mismos beneficios de la postdilucional que permite lograr volúmenes de ultrafiltración dentro de los objetivos planteados. Creemos podría ser útil en pacientes con flujos sanguíneos limitados para lo cual habría que diseñar nuevos estudios. La PPF aporta información complementaria a la PTM (AU)

Background: On line haemodiafiltration provides the greatest clearance for low and high-molecular weight uremic toxins, which is associated with a lower risk of mortality in our patients. Nowadays, there’s increasing evidence about the need of achieving at least 20 litters ultrafiltration in postdilution mode and70% reduction of beta-2-microglobulin (B2M), however it requires a vascular access’s high blood flow. Unfortunately, we do not succeed in these objectives because of our patients being older, diabetic and with poor vascular access; in this situation highblood flows are more difficult to get at the expense of lower postdilution exchange volumes. The aim of this study was to assess the efficiency of OL-S-HDF to obtain an equivalent ultrafiltration volume as 20 L in OL-postdilution-HDF (OL-P-HDF). OL-SHD Finitially begins in postdilution mode changing to predilution once the transmembrane pressure (TMP) reached 250 mmHg. Methods: We performed one high-flux HD session (HF-HD), one OL-P-HDF session and one OL-S-HDF session in each of the 16adult patients who participated during 3 consecutive weeks. We compared the clearance rates of low and middle molecules such asurea, creatinine, B2M, myoglobulin and levels of albumin and haematocrit between the 3 different techniques. We measured the pre-filter pressure (PFP) by a manometer set before the dialyzer. Results: The main characteristics of the sessions are described in table Nº1. There wasn¿t significant difference in Kt/V, urea and creatinine removal between the three techniques. B2M and myoglobulin¿s clearance rates were significantly higher in both hemodiafiltration modes than in HF-HD (p = 0.000), however we didn¿t find differences between OL-P-HDF and OL-S-HDF. There was a direct correlation between PFP and TMP along the sessions in every technique (p < 0.05). We found that PFP was better than TMP to correlate with pre-dialysis levels of albumin and haematocrit and also with the haemoconcentration percentage at the end of the sessions. Conclusions: This study confirms that OL-S-HDF is as good as OL-P-HDF and it could be a useful technique to treat patients with suboptimal access¿s blood flow to get to achieve ultrafiltration volumes within the objectives. PFP could offer extra information than TMP (AU)

[On-line sequential hemodiafiltration (HDF-OL-S): a new therapeutic option]. / Hemodiafiltración en línea secuencial (HDF-OL-S): una nueva opción terapéutica.

BACKGROUND: on line haemodiafiltration provides the greatest clearance for low and high-molecular weight uremic toxins, which is associated with a lower risk of mortality in our patients. Nowadays, there's increasing evidence about the need of achieving at least 20 litters ultrafiltration in postdilution mode and 70% reduction of beta-2-Microglobulin (B2M), however it requires a vascular access's high blood flow. Unfortunately, we do not succeed in these objectives because of our patients being older, diabetic and with poor vascular access; in this situation high blood flows are more difficult to get at the expense of lower post-dilution exchange volumes. The aim of this study was to assess the efficiency of OL-S-HDF to obtain an equivalent ultrafiltration volume as 20 L in OL-postdilution-HDF (OL-P-HDF). OL-S-HDF initially begins in postdilution mode changing to predilution once the transmembrane pressure (TMP) reached 250 mmHg. METHODS: we performed one high-flux HD session (HF-HD), one OL-P-HDF session and one OL-S-HDF session in each of the 16 adult patients who participated during 3 consecutive weeks. We compared the clearance rates of low and middle molecules such as urea, creatinine, B2M, myoglobulin and levels of albumin and haematocrit between the 3 different techniques. We measured the pre-filter pressure (PFP) by a manometer set before the dialyzer. RESULTS: The main characteristics of the sessions are described in table N1. There wasn't significant difference in Kt/V, urea and creatinine removal between the three techniques. B2M and myoglobulin's clearance rates were significantly higher in both hemodiafiltration modes than in HF-HD (p=0.000), however we didn't find differences between OL-P-HDF and OL-S-HDF. There was a direct correlation between PFP and TMP along the sessions in every technique (p<0.05). We found that PFP was better than TMP to correlate with pre-dialysis levels of albumin and haematocrit and also with the haemoconcentration percentage at the end of the sessions. CONCLUSIONS: This study confirms that OL-S-HDF is as good as OL-P-HDF and it could be a useful technique to treat patients with suboptimal access's blood flow to get to achieve ultrafiltration volumes within the objectives. PFP could offer extra information than TMP.

[Peripheral vascular disease: prevalence, mortality and relationship with inflammation in hemodialysis]. / Enfermedad Vascular Periférica: Prevalencia, Mortalidad y Asociación con Inflamación en Hemodiálisis.

Peripheral vascular disease (PVD) is a common disease among patients undergoing hemodialysis leading to increase morbidity and mortality with a high risk of inflammation and sepsis. The aim of the present study was to determinate PVD prevalence in our hemodialysis population and association with inflammation. The study sample consisted of 220 patients prevalents in hemodialysis. A basal study was made in 2001 and a follow up for 47 months. Data were collected retrospectively. PVD diagnosis was made attending to limb pulses and doppler in revisions. Diagnosis was classified as rest pain, ischemic ulceration and gangrene. Among a total of 220 patients, 89 had prevalent PVD. Thirty per cent had rest pain, 6,5% had ischemic ulceration and 3% had gangrene. Ninety five per cent underwent medical treatment, 0,5% were treated by percutaneous transluminal angioplasty (PTA), 2% were treated with surgical revascularization and 2,5% were treated with amputation. Patients with PVD were older, with higher Charlson index, diabetes, they hay higher CRP and fibrinogen serum levels; and lower albumin and prealbumine serum levels. Survival PVD was decreased in Kaplan-Meier (log rank =12,4; p<0,000). Adjusted Cox regression analysis revealed that PVD (p =0,034; OR =2,10; IC [1,06 ; 4,23]) ; age (p =0,001; OR =1,06; IC [1,03 ; 1,09]) and low serum albumin levels (p =0,012; OR =0,93; IC [0,89 ; 0,98]) predicted significantly the risk of mortality. PVD is an independent mortality risk factor in hemodialysis patients. An early diagnosis and treatment are able with examination and doppler. In our sample, a few patients are treated with PTA or surgical revascularization. There is an association between PVD and inflammation.

Enfermedad vascular periférica: prevalencia, mortalidad y asociación con inflamación enhemodiálisis / Peripheral vascular disease: prevalence, mortality and association with inflammation in haemodialysis

La enfermedad vascular periférica es una complicación frecuente en la población en hemodiálisis que contribuye a aumentar su morbi-mortalidad, al favorecer el estado inflamatorio, la malnutrición y las complicaciones severas como la isquemia y la sepsis secundaria. El objetivo del estudio fue analizar la prevalencia de enfermedad vascular periférica en nuestra población en hemodiálisis, su repercusión en la mortalidad y su asociación con parámetros de inflamación y malnutrición. Fueron incluidos 220 pacientes prevalentes en hemodiálisis, del área perteneciente a nuestro centro hospitalario. Se realizó un estudio basal en el año 2001 y se siguieron durante 48 (..) (AU)

Peripheral vascular disease (PVD) is a common disease among patients undergoing hemodialysis leading to increase morbidity and mortality with a high risk of inflammation and sepsis. The aim of the present study was to determinate PVD prevalence in our hemodialysis population and association with inflammation. The study sample consisted of 220 patients prevalents in hemodialysis. A basal study was made in 2001 and a follow up for 47months. Data were collected retrospectively. PVD diagnosis was made attending to limb pulses and doppler in revisions. Diagnosis was classified as rest pain, ischemic ulceration and gangrene. Among a total of 220 patients, 89 had prevalent PVD. Thirty percent had rest pain, 6,5% had ischemic ulceration and 3% had gangrene. Ninety five per cent underwent medical treatment,0,5% were treated by per cutaneous transluminal angioplasty(PTA), 2% were treated with surgical revascularization and 2,5%were treated with amputation. Patients with PVD were older, with higher Charlson index, diabetes, they hay higher CRP and fibrinogen serum levels; and lower albumin and prealbumineserum levels. Survival PVD was decreased in Kaplan-Meier (logrank 012,4; p < 0,000). Adjusted Cox regression analysis revealed that PVD (p = 0,034; OR = 2,10; IC [1,06; 4,23]) ; age (p =0,001; OR = 1,06; IC [1,03; 1,09]) and low serum albumin levels(p = 0,012; OR = 0,93; IC [0,89; 0,98]) predicted significantly the risk of mortality. PVD is an independent mortality risk factor inhemodialysis patients. An early diagnosis and treatment are able with examination and doppler. In our sample, a few patients are treated with PTA or surgical revascularization. There is an association between PVD and inflammation (AU)

Cambios clínicos y analíticos al sustituir el líquido de diálisis convencional por uno sin acetato / Clinical and analytical changes in hemodialysis without acetate

Introducción: El objetivo de dicho estudio fue evaluar los cambios en la acetatemia durante la hemodiálisis (HD) en pacientes con líquido de diálisis (LD) convencional con acetato y en pacientes con LD con clorhídrico (HCl) y analizar sus efectos sobre la clínica y sobre distintos parámetros analíticos. Material y métodos: 14 pacientes en programa de HD estable (11 hombres) de 61 ± 15 años de edad fuerondializados durante 1 mes con el LD convencional con acetato y durante el segundo mes con el LD con HCl (sin acetato). Se obtuvieron análisis pre y post-diálisisla tercera sesión de las semanas 1 y 4 en cada uno de los períodos (con y sin acetato).Resultados: Las medias de los acetatos pre-diálisis fueron similares en ambos grupos, mientras que las medias de los acetatos post-diálisis fueron significativamente superiores en el grupo tratado con el LD convencional (0,48 ± 0,64 vs 0,18 ±0,23 mmol/L, p = 0,024). Tampoco hallamos diferencias significativas entre los 2 grupos en cuanto a la presencia de valores de acetato pre-diálisis patológicos, mientras sí hallamos un mayor porcentaje valores patológicos de acetato post-diálisis enel grupo tratado con LD convencional respecto al grupo del HCl (67% vs 21%, p = 0,001). Los niveles plasmáticos de IL-6 fueron significativamente superiores en el periodo de diálisis con acetato (31,7 ± 24,7 vs 18,7 ± 10,3 pg/ml, p = 0,014), aunque no se acompañaron de un aumento de otros marcadores inflamatorios como la LBP,el TNF-alfa o la PCR dializante el mismo periodo. No hallamos diferencias estadísticamente significativas en los otros parámetros evaluados excepto en la variación de las concentraciones de sodio, cloro y bicarbonato. Conclusiones: El LD sin acetato no expone a los pacientes a concentraciones elevadas de acetato consiguiendo que la mayoría de pacientes (79%) termine la HD con una acetatemia dentro del rango fisiológico.El uso de LD sin acetato es seguro y bien tolerado por los pacientes en hemodiálisis, aunque su traducción clínica debe ser evaluada en estudios prospectivosa más largo plazo (AU)

Background: the purpose of this study was to evaluate blood acetate levels and its correlation with clinical and analytical changes in hemodialysis patients treated with standard bicarbonate dialysate compared to treatment with acetate-free bicarbonate dialysate. Methods: Fourteen patients on hemodialysis (11 male) with mean age of 61 ± 15 years were treated with conventional bicarbonate dialysate for 1 month andthen switched to acetate-free bicarbonate dialysate for another month. Blood samples were drawn at the third session of first and fourth week of each type of dialysis.Results: Pre-dialysis blood acetate levels were similar in both groups, whereas postdialysis blood acetate levels were higher in patients treated with conventional bicarbonate dialysate (0.48 ± 0.64 vs 0.18 ± 0.23 mmol/L, p = 0.024). Moreover, both periods had similar percentage of patients with pre-dialysis blood acetate levels in the pathologic range, whereas this percentage was higher in post-dialysis samples from patients treated with conventional bicarbonate dialysate respect to acetate-free dialysate (67% vs 21%, p = 0.001). Serum levels of interleukin-6 were statistically higher in the period with conventional bicarbonate dialysate (31.7 ± 24.7 vs 18,7 ± 10,3 pg/ml, p = 0,014), even though other inflammatory markers such as LBP, TNF-alfa and CRP failed to increase in the same period. We didn’t found significant differences in the other parameters studied except for the changes in serum concentrationsof sodium, chloride and bicarbonate. Conclusions: Acetate-free bicarbonate dialysate does not expose patients to a big amount of acetate and allows that the majority of patients finished hemodialysis with blood acetate levels in the physiologic ranges. Acetate-free dialysate was safe and well tolerated by our hemodialysis patients, although clinical advantages derived from its use should be evaluated in long-termprospective studies (AU)

[Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study]. / Estudio de dos cohortes de pacientes para evaluar el índice de resistencia a epoetina alfa y a darbepoetin alfa en pacientes en hemodiálisis crónica.

The effectiveness of the erythropoietic response can be evaluated using the resistance index (RI) to erythropoietic agents (EA) that measures the relationship between the dose administered and the hemoglobin levels attained. In a hemodialysis population, the RI is associated with several clinical and biochemical parameters, such as albumin levels, C-reactive protein (CRP), body mass index (BMI) and Kt/V. This index therefore reflects an important group of parameters that indicate comorbidities and measures the effectiveness of the treatment received. A substantial proportion of chronic hemodialysis patients show a relative resistance to human recombinant erythropoietin (rHuEPO) and require high doses to reach hemoglobin levels above 11 g/dl. Darbepoetin alpha is a new erythropoietic agent with a longer half-life than rHuEPO and greater biological activity in vivo. Furthermore, it remains at clinically effective plasma levels for much longer than rHuEPO. This study evaluated the effect on RI of switching from epoetin alpha to darbepoetin alpha in hemodialysis patients requiring i.v. rHuEPO at either high ( >10,000 UI/w) or low ( <4,000 UI/w) doses, compared to a control group receiving epoetin alpha. Unlike the control group, both groups of patients who switched to darbepoetin alpha showed a reduction in RI and a progressive reduction in the dose required of darbepoetin alpha with respect to the equivalent dose at treatment conversion. In the group requiring high doses, darbepoetin alpha RI (DRI) at week 24 was a significant 23.9% lower than epoetin alpha RI (ERI) at conversion (week 0) (p <0.01). In the group requiring low doses, DRI at week 24 was 13.4% lower than the ERI at conversion (p = NS). In both control groups, ERI at week 24 was higher than ERI at week 0. All groups showed stable hemoglobin levels across the study, with mean levels between 11.5 and 13.3 g/dl. CRP at week 24 was significantly related to albumin levels (p <0.001). In conclusion, switching hemodialysis patients from epoetin alpha to darbepoetin alpha was associated with a significant improvement in RI in the group of patients with high doses of EA, which we consider to be an important indicator of the effectiveness and quality of the treatment administered.

Estudio de dos cohortes de pacientes para evaluar el índice de resistencia a epoetina alfa y a darbepoetin alfa en pacientes en hemodiálisis crónica / Resistance index to epoetin alfa and to darbepoetin-alfa in chronic hemodialysis patients: a cohort study

La efectividad de la respuesta en la estimulación eritropoyética se puede expresar por el índice de resistencia (IR) a los agentes estimuladores de la eritropoyesis, que expresa la relación entre la dosis administrada del agente y las concentraciones de hemoglobina mantenidas. El IR de una población en hemodiálisis se relaciona con una serie de parámetros clínicos y bioquímicos de la hemodiálisis, como la concentración de albúmina, la proteína C reactiva (PCR), el índice de la masa corporal (IMC) y el Kt/V y se presenta, por tanto, como un índice de valoración de un conjunto muy importante de parámetros que expresan la patología comórbida de los pacientes y la calidad del tratamiento recibido. Una proporción considerable de pacientes en hemodiálisis crónica presentan una resistencia relativa o respuesta subóptima a la eritropoyetina recombinante humana (rHuEPO), por lo que precisan dosis elevadas de esta proteína para alcanzar unas concentraciones de hemoglobina superiores a los 11 g/dl. Darbepoetin alfa es una nueva proteína estimuladora de la eritropoyesis con un perfil farmacocinético caracterizado por una semivida mucho más prolongada que la de rHuEPO y una mayor actividad biológica in vivo, permaneciendo mucho más tiempo en plasma a concentraciones clínicamente eficaces en comparación con rHuEPO. El presente estudio evalúa el resultado de cambiar la administración de epoetina alfa a darbepoetin alfa sobre la efectividad y la calidad del tratamiento, determinadas mediante el IR, en pacientes en hemodiálisis que requieren un tratamiento a dosis altas (> 10.000 UI/sem) o bajas (< 4.000 UI/sem) de epoetina alfa por vía i.v., en comparación con un grupo control que siguió recibiendo epoetina alfa. En los dos grupos de pacientes que cambiaron a darbepoetin alfa, se registró una disminución del IR y de la dosis necesaria de darbepoetin alfa con relación a la dosis equivalente en el momento de la conversión, que no fue observada en los grupos control. En el grupo que precisó dosis altas, el IR a darbepoetin alfa (IRD) al final del estudio (semana 24), disminuyó un 23,9% respecto al IR a epoetina alfa (IRE) en el momento de la conversión (semana 0), una disminución que fue estadísticamente significativa (p < 0,01). De forma similar, en el grupo tratado con dosis bajas que cambió a darbepoetin alfa, se registró una disminución del IRD al final del estudio del 13,4% respecto al IRE en el momento de la conversión (p = NS). En ambos grupos control el IRE final aumentó respecto al inicial. Las concentraciones de hemoglobina se mantuvieron estables en todos los grupos a lo largo de todo el período de seguimiento del estudio, con unos valores medios que oscilaron entre los 11,5 y los 13,3 g/dl. Los valores de la PCR al final del estudio (semana 24) mostraron una relación significativa con las concentraciones de albúmina (p < 0,001). En conclusión, la conversión de epoetina alfa a darbepoetin alfa en pacientes en hemodiálisis tuvo como resultado una mejoría significativa del IR al tratamiento en los pacientes con mayores necesidades de AEE

The effectiveness of the erythropoietic response can be evaluated using the resistance index (RI) to erythropoietic agents (EA) that measures the relationship between the dose administered and the hemoglobin levels attained. In a hemodialysis population, the RI is associated with several clinical and biochemical parameters, such as albumin levels, C-reactive protein (CRP), body mass index (BMI) and Kt/V. This index therefore reflects an important group of parameters that indicate comorbidities and measures the effectiveness of the treatment received. A substantial proportion of chronic hemodialysis patients show a relative resistance to human recombinant erythropoietin (rHuEPO) and require high doses to reach hemoglobin levels above 11 g/dl. Darbepoetin alfa is a new erythropoietic agent with a longer half-life than rHuEPO and greater biological activity in vivo. Furthermore, it remains at clinically effective plasma levels for much longer than rHuEPO. This study evaluated the effect on RI of switching from epoetin alfa to darbepoetin alfa in hemodialysis patients requiring iv rHuEPO at either high (> 10,000 UI/w) or low (< 4,000 UI/w) doses, compared to a control group receiving epoetin alfa. Unlike the control group, both groups of patients who switched to darbepoetin alfa showed a reduction in RI and a progressive reduction in the dose required of darbepoetin alfa with respect to the equivalent dose at treatment conversion. In the group requiring high doses, darbepoetin alfa RI (DRI) at week 24 was a significant 23.9% lower than epoetin alfa RI (ERI) at conversion (week 0) (p < 0.01). In the group requiring low doses, DRI at week 24 was 13.4% lower than the ERI at conversion (p = NS). In both control groups, ERI at week 24 was higher than ERI at week 0. All groups showed stable hemoglobin levels across the study, with mean levels between 11.5 and 13.3 g/dl. CRP at week 24 was significantly related to albumin levels (p < 0.001). In conclusion, switching hemodialysis patients from epoetin alfa to darbepoetin alfa was associated with a significant improvement in RI in the group of patients with high doses of EA, which we consider to be an important indicator of the effectiveness and quality of the treatment administered

[Clinical and analytical changes in hemodialysis without acetate]. / Cambios clínicos y analíticos al sustituir el líquido de diálisis convencional por uno sin acetato.

BACKGROUND: the purpose of this study was to evaluate blood acetate levels and its correlation with clinical and analytical changes in hemodialysis patients treated with standard bicarbonate dialysate compared to treatment with acetate-free bicarbonate dialysate. METHODS: fourteen patients on hemodialysis (11 male) with mean age of 61 15 years, were treated with conventional bicarbonate dialysate for 1 month and then switched to acetate-free bicarbonate dialysate for another month. Blood samples were drawn at the third session of first and fourth week of each type of dialysis. RESULTS: Pre-dialysis blood acetate levels were similar in both groups, whereas post-dialysis blood acetate levels were higher in patients treated with conventional bicarbonate dialysate (0.48+/- 0.64 vs. 0.18+/-0.23 mmol/L, p=0.024). Moreover, both periods had similar percentage of patients with pre-dialysis blood acetate levels in the pathologic range, whereas this percentage was higher in post-dialysis samples from patients treated with conventional bicarbonate dialysate respect to acetate-free dialysate (67% vs. 21%, p=0.001). Serum levels of interleukin-6 were statistically higher in the period with conventional bicarbonate dialysate (31.7+/- 24.7 vs. 18.7+/- 10.3 pg/ml, p=0.014), even though other inflammatory markers such as LBP, TNF- and CRP failed to increase in the same period. We didn't found significant differences in the other parameters studied except for the changes in serum concentrations of sodium, chloride and bicarbonate. CONCLUSIONS: Acetate-free bicarbonate dialysate does not expose patients to a big amount of acetate and allows that the majority of patients finished hemodialysis with blood acetate levels in the physiologic ranges. Acetate-free dialysate was safe and well tolerated by our hemodialysis patients, although clinical advantages derived from its use should be evaluated in long-term prospective studies.

[Differences in health-related quality of life between male and female hemodialysis patients]. / Diferencias en la calidad de vida relacionada con la salud entre hombres y mujeres en tratamiento en hemodíalisis.

BACKGROUND: Previous studies in renal patients have reported that women perceive a lower health-related quality of life (HRQOL) than men: however, these studies have been carried out without taking into account the gender-related differences shown in general population samples. The aims of the present study are: a) to define the HRQOL dimensions in which there are differences between men and women on chronic hemodialysis (HD), correcting then the differences on the generic dimensions by means of standardization by age and gender of the obtained scores, using Spanish normative data, and b) to identify the variables that cause these possible gender-related differences on HRQOL. METHODS: A cross-sectional multi-center study was carried out with 152 patients (69 men and 83 women) receiving HD treatment in 43 Spanish centers, using the KDQOL-SF to evaluate their HRQOL. The generic KDQOL-SF scores were standardized by age and gender using Spanish normative data. Sociodemographic, clinical and psychosocial variables were also collected on each patient. A MANOVA was carried out to study the variables associated with the gender-related differences on HRQOL. The sociodemographic, clinical and psychosocial variables showing significant differences between men and women in the previous univariate analysis were entered as covariates. RESULTS: The KDQOL-SF scores showed statistically significant differences between men and women in four scales: physical functioning, emotional role limitation, social function and emotional well-being. In contrast, standardized scores showed no differences between men and women in the profile or degree of HRQOL impairment. Although statistically significant gender-related differences were shown in educational level, employment, haemoglobin, Kt/V, trait anxiety and depressive symptoms, only the last two variables showed an independent effect on the differences in HRQOL. CONCLUSION: Impaired HRQOL in women on HD reflects the gender-related differences that are also shown in the general population, and they are related to the higher prevalence of trait anxiety and depressive symptoms in women.

[Cardiovascular risk factors in chronic renal failure]. / Factores de riesgo cardiovascular en la enfermedad renal crónica.

Cardiovascular complications are the main cause of death in patients with chronic renal disease. These complications are due to two important morphological changes. Firstly, left ventricular hypertrophy together with the changes in the cardiac remodelling and myocardiac fibrosis constitute the lesion with the highest incidence in renal chronic disease. Secondly, disease in the large arteries (macrovascular disease) involve two types lesions: Artherosclerosis, which is characterised by the formation of plaques in the intima arterial membrane and artherosclerosis due to lesions in the media arterial membrane, which causes a loss in elasticity of the arterial tree.

Factores de riesgo cardiovascular en la enfermedad renal crónica / Cardiovascular risk factors in chronic renal failure

Las complicaciones cardiovasculares constituyen la principal causa de muerte en pacientes con enfermedad renal crónica. Estas complicaciones son el resultado clínico de dos grandes alteraciones morfológicas. La primera es la hipertrofia ventricular izquierda, que junto con las alteraciones en el remodelado cardíaco y la fibrosis miocárdica constituye la lesión más prevalente en la enfermedad renal crónica. El segundo bloque de alteraciones morfológicas está formado por la enfermedad macrovascular o de grandes arterias, en la que a su vez hay que diferenciar dos tipos de lesiones diferentes: la aterosclerosis caracterizada por la formación de la placa en la capa íntima arterial y la arteriosclerosis o lesión de la capa media, que confiere una rigidez aumentada del árbol arterial (AU)

Cardiovascular complications are the main cause of death in patients with chronic renal disease. These complications are due to two important morphological changes. Firstly, left ventricular hypertrophy together with the changes in the cardiac remodelling and miocardiac fibrosis constitute the lesion with the highest incidence in renal chronic disease. Secondly, disease in the large arteries (macrovascular disease) involve two types lesions: Artherosclerosis, which is characterised by the formation of plaques in the intima arterial membrane and artherosclerosis due to lesions in the media arterial membrane, which causes a loss in elasticity of the arterial tree (AU)

Quality of life in end-stage renal disease patients.

Health-related quality of life (QOL) refers to the measure of a patient's functioning, well-being, and general health perception in each of three domains: physical, psychological, and social. Along with survival and other types of clinical outcomes, patient QOL is an important indicator of the effectiveness of the medical care they receive. QOL of patients with end-stage renal disease is influenced by the disease itself and by the type of replacement therapy. Numerous studies have identified the effect of such factors as anemia, age, comorbidity, and depression on QOL. Most of these factors appear during the predialysis period, and the adequate management of some of them could influence patient outcomes. Among replacement therapies, transplantation appears to give the best QOL for large groups of patients. No conclusive data exist to prove differences in QOL between hemodialysis patients and peritoneal dialysis patients. In the case of elderly patients or those with a high degree of comorbidity, the best treatment option should be assessed in each individual case, taking all possible factors into account. Finally, it has been proven that physical and mental function are inversely correlated with the risk for hospitalization and mortality.